Combination therapy with platinum and etoposide of brain metastases from breast carcinoma

Giorgio Cocconi; Renata Lottici; Giancarlo Bisagni; Marisa Bacchi; Maurizio Tonato; Rodolfo Passalacqua; Corrado Boni; Virginio Belsanti; Pellegrino Bassi

doi:10.3109/07357909009012049

Combination therapy with platinum and etoposide of brain metastases from breast carcinoma

Giorgio Cocconi, Renata Lottici, Giancarlo Bisagni, Marisa Bacchi, Maurizio Tonato, Rodolfo Passalacqua, Corrado Boni, Virginio Belsanti, Pellegrino Bassi

Arcispedale Santa Maria Nuova

Research output: Contribution to journal › Article › peer-review

Abstract

Twenty-two consecutive patients with brain metastases from breast carcinoma were treated with a combination of platinum (100 mg/m² day 1) and etoposide (100 mg/m² days 4,6,8) every three weeks. Five (23% achieved a complete response (CR) while 7 (32% obtained a partial response (PR) for an overall response rate of 55% The 95% confidence interval for combined CR and PR was 34-76% Five patients received brain irradiation after reaching the maximum degree of objective remission by chemotherapy. Median duration of combined CR plus PR was 40 weeks (12 + 152). Median duration of survival was 58 weeks (2; 208+ Fifty-five percent of the patients were alive at one year. Our study demonstrates that this combination treatment is highly effective in the management of brain metastases from breast carcinoma.

Original language	English
Pages (from-to)	327-334
Number of pages	8
Journal	Cancer Investigation
Volume	8
Issue number	3-4
DOIs	https://doi.org/10.3109/07357909009012049
Publication status	Published - 1990

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.3109/07357909009012049

Cite this

Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. / Cocconi, Giorgio; Lottici, Renata; Bisagni, Giancarlo; Bacchi, Marisa; Tonato, Maurizio; Passalacqua, Rodolfo; Boni, Corrado; Belsanti, Virginio; Bassi, Pellegrino.

In: Cancer Investigation, Vol. 8, No. 3-4, 1990, p. 327-334.

Research output: Contribution to journal › Article › peer-review

@article{66d33155530549aea3f0e8e77990b3d9,

title = "Combination therapy with platinum and etoposide of brain metastases from breast carcinoma",

abstract = "Twenty-two consecutive patients with brain metastases from breast carcinoma were treated with a combination of platinum (100 mg/m2 day 1) and etoposide (100 mg/m2 days 4,6,8) every three weeks. Five (23% achieved a complete response (CR) while 7 (32% obtained a partial response (PR) for an overall response rate of 55% The 95% confidence interval for combined CR and PR was 34-76% Five patients received brain irradiation after reaching the maximum degree of objective remission by chemotherapy. Median duration of combined CR plus PR was 40 weeks (12 + 152). Median duration of survival was 58 weeks (2; 208+ Fifty-five percent of the patients were alive at one year. Our study demonstrates that this combination treatment is highly effective in the management of brain metastases from breast carcinoma.",

author = "Giorgio Cocconi and Renata Lottici and Giancarlo Bisagni and Marisa Bacchi and Maurizio Tonato and Rodolfo Passalacqua and Corrado Boni and Virginio Belsanti and Pellegrino Bassi",

year = "1990",

doi = "10.3109/07357909009012049",

language = "English",

volume = "8",

pages = "327--334",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "3-4",

}

TY - JOUR

T1 - Combination therapy with platinum and etoposide of brain metastases from breast carcinoma

AU - Cocconi, Giorgio

AU - Lottici, Renata

AU - Bisagni, Giancarlo

AU - Bacchi, Marisa

AU - Tonato, Maurizio

AU - Passalacqua, Rodolfo

AU - Boni, Corrado

AU - Belsanti, Virginio

AU - Bassi, Pellegrino

PY - 1990

Y1 - 1990

N2 - Twenty-two consecutive patients with brain metastases from breast carcinoma were treated with a combination of platinum (100 mg/m2 day 1) and etoposide (100 mg/m2 days 4,6,8) every three weeks. Five (23% achieved a complete response (CR) while 7 (32% obtained a partial response (PR) for an overall response rate of 55% The 95% confidence interval for combined CR and PR was 34-76% Five patients received brain irradiation after reaching the maximum degree of objective remission by chemotherapy. Median duration of combined CR plus PR was 40 weeks (12 + 152). Median duration of survival was 58 weeks (2; 208+ Fifty-five percent of the patients were alive at one year. Our study demonstrates that this combination treatment is highly effective in the management of brain metastases from breast carcinoma.

AB - Twenty-two consecutive patients with brain metastases from breast carcinoma were treated with a combination of platinum (100 mg/m2 day 1) and etoposide (100 mg/m2 days 4,6,8) every three weeks. Five (23% achieved a complete response (CR) while 7 (32% obtained a partial response (PR) for an overall response rate of 55% The 95% confidence interval for combined CR and PR was 34-76% Five patients received brain irradiation after reaching the maximum degree of objective remission by chemotherapy. Median duration of combined CR plus PR was 40 weeks (12 + 152). Median duration of survival was 58 weeks (2; 208+ Fifty-five percent of the patients were alive at one year. Our study demonstrates that this combination treatment is highly effective in the management of brain metastases from breast carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0025059696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025059696&partnerID=8YFLogxK

U2 - 10.3109/07357909009012049

DO - 10.3109/07357909009012049

M3 - Article

C2 - 2207757

AN - SCOPUS:0025059696

VL - 8

SP - 327

EP - 334

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 3-4

ER -

Combination therapy with platinum and etoposide of brain metastases from breast carcinoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this